1. Home
  2. MESO vs ATEN Comparison

MESO vs ATEN Comparison

Compare MESO & ATEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MESO
  • ATEN
  • Stock Information
  • Founded
  • MESO 2004
  • ATEN 2004
  • Country
  • MESO Australia
  • ATEN United States
  • Employees
  • MESO N/A
  • ATEN N/A
  • Industry
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • ATEN EDP Services
  • Sector
  • MESO Health Care
  • ATEN Technology
  • Exchange
  • MESO Nasdaq
  • ATEN Nasdaq
  • Market Cap
  • MESO 1.7B
  • ATEN 1.5B
  • IPO Year
  • MESO N/A
  • ATEN 2014
  • Fundamental
  • Price
  • MESO $12.48
  • ATEN $16.34
  • Analyst Decision
  • MESO Buy
  • ATEN Buy
  • Analyst Count
  • MESO 4
  • ATEN 2
  • Target Price
  • MESO $18.00
  • ATEN $21.00
  • AVG Volume (30 Days)
  • MESO 305.9K
  • ATEN 1.8M
  • Earning Date
  • MESO 02-26-2025
  • ATEN 04-29-2025
  • Dividend Yield
  • MESO N/A
  • ATEN 1.47%
  • EPS Growth
  • MESO N/A
  • ATEN 26.41
  • EPS
  • MESO N/A
  • ATEN 0.67
  • Revenue
  • MESO $5,670,000.00
  • ATEN $261,696,000.00
  • Revenue This Year
  • MESO $228.57
  • ATEN $9.39
  • Revenue Next Year
  • MESO $356.77
  • ATEN $7.96
  • P/E Ratio
  • MESO N/A
  • ATEN $24.37
  • Revenue Growth
  • MESO N/A
  • ATEN 3.97
  • 52 Week Low
  • MESO $4.60
  • ATEN $12.27
  • 52 Week High
  • MESO $22.00
  • ATEN $21.90
  • Technical
  • Relative Strength Index (RSI)
  • MESO 34.58
  • ATEN 31.52
  • Support Level
  • MESO $13.60
  • ATEN $16.95
  • Resistance Level
  • MESO $14.45
  • ATEN $17.98
  • Average True Range (ATR)
  • MESO 0.49
  • ATEN 0.60
  • MACD
  • MESO 0.02
  • ATEN -0.11
  • Stochastic Oscillator
  • MESO 23.50
  • ATEN 8.10

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

About ATEN A10 Networks Inc.

A10 Networks Inc is a provider of security and infrastructure solutions for on-premises, hybrid cloud, and edge-cloud environments of its multinational enterprise, communication, cloud and web service provider customers who strive to provide business-critical applications and networks that are secure, available, and efficient. As cyber-attacks increase in volume and complexity, the company integrates security and artificial intelligence (AI) enabled capabilities in its solutions that enable its customers to continue to adapt to market trends in hybrid cloud, AI-ready data centers and the ever-increasing need for high-performance, high availability and low latency. The company generates the maximum of its revenue from Americas.

Share on Social Networks: